mecasermin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
insulin-like growth factors	5009	68562-41-4

Description:

Molecule	Description
Synonyms: mecasermin recombinant mecasermin increlex somatomedin C Somatomedin-C IGF1 insulin-like growth factor 1	Recombinant form of endogenous Insulin-like Growth Factor 1 exhibiting mitogenic activity. Clinical Use: Diabetes Mellitus and Amyotrophic Lateral Sclerosis. Molecular weight: 7648.71 Formula: C331H512N94O101S7 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 3126.93 ALOGS: ROTB: None

Molecule

Description

Synonyms:

mecasermin recombinant
mecasermin
increlex
somatomedin C
Somatomedin-C
IGF1
insulin-like growth factor 1

Recombinant form of endogenous Insulin-like Growth Factor 1 exhibiting mitogenic activity. Clinical Use: Diabetes Mellitus and Amyotrophic Lateral Sclerosis.

Molecular weight: 7648.71
Formula: C331H512N94O101S7
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 3126.93
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 8, 2007	EMA
Aug. 30, 2005	FDA	IPSEN INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	58.76	41.45	19	282	58994	53289771
Tonsillar hypertrophy	43.93	41.45	7	294	863	53347902

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tonsillar hypertrophy	120.19	49.62	19	646	602	32512259
Product dose omission issue	60.76	49.62	33	632	102542	32410319
Adenoidal hypertrophy	56.77	49.62	8	657	112	32512749
Hypoglycaemia	51.23	49.62	24	641	54358	32458503

Pharmacologic Action:

Source	Code	Description
ATC	H01AC03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists
MeSH PA	D006133	Growth Substances

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Laron-type isolated somatotropin defect	indication	38196001	DOID:9521

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Insulin-like growth factor 1 receptor	Kinase	P08069	IGF1R_HUMAN	AGONIST	IC50	8.31		SCIENTIFIC LITERATURE	DRUG LABEL
Insulin receptor	Kinase	P06213	INSR_HUMAN		IC50	5.85		SCIENTIFIC LITERATURE

External reference:

ID	Source
D03297	KEGG_DRUG
4024932	VUID
N0000023113	NUI
4024932	VANDF
CHEBI:80343	CHEBI
CHEMBL1201716	ChEMBL_ID
C000604197	MESH_SUPPLEMENTAL_RECORD_UI
4971	IUPHAR_LIGAND_ID
6372	INN_ID
DB01277	DRUGBANK_ID
7GR9I2683O	UNII
274403	RXNORM
20506	MMSL
71163	MMSL
d05636	MMSL
011016	NDDF
418157000	SNOMEDCT_US
418845006	SNOMEDCT_US
5699003	SNOMEDCT_US
C0904505	UMLSCUI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Increlex	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1040	INJECTION, SOLUTION	40 mg	SUBCUTANEOUS	BLA	30 sections
Cosmeceutical Mask Pack	HUMAN OTC DRUG LABEL	6	60709-102	PATCH	0.04 mg	TOPICAL	unapproved drug other	9 sections
Dermaheal Cosmeceutical Mask Pack Plus	HUMAN OTC DRUG LABEL	6	60709-105	PATCH	0.04 mg	TOPICAL	unapproved drug other	9 sections